Rank #1018BCRX

BioCryst Pharmaceuticals, Inc.

$7.48

3.03% (Daily)

Market Cap

$1.86B

Revenue

$599.82M

Rank by MCap

#1018

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Mr. Charles K. Gayer

Headquarters

Durham, NC

Employees

580

About BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in p...